EEG Neural Complexity for Agomelatine Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical practices for treating major depressive disorder and bipolar disorder lack effective biological or quantitative measures to guide the selection of antidepressant medications, leading to a trial-and-error approach and suboptimal treatment outcomes.
Innovation Solution
The use of electroencephalography (EEG) measures, specifically high EEG sample entropy in the low gamma frequency range, to predict which patients are most likely to benefit from agomelatine treatment, allowing for personalized medication selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If clinical care for depression involves assessment and diagnosis based on clinician-assessed and patient-reported symptoms without biological or quantitative behavioral variables, then the diagnostic process remains simple and accessible, but the precision of medication selection deteriorates leading to trial-and-error approaches
Solution Approach 1:
The patent introduces EEG-based neural complexity measures as an intermediary between clinical assessment and medication selection. These objective biological markers serve as a mediator that translates brain activity patterns into actionable insights for antidepressant choice, bridging the gap between simple clinical evaluation and precise pharmacological targeting without replacing the clinical assessment process
Solution Approach 2:
The patent replaces the subjective, mechanical process of trial-and-error medication selection with an objective, biologically-based decision support system. By substituting clinician guesswork and patient reporting with quantifiable EEG-derived neural complexity metrics, the system transforms medication selection from a mechanical trial process into a guided, evidence-based intervention
2Reliability
If multiple antidepressant trials are conducted through trial-and-error approach, then the likelihood of finding an effective treatment increases, but the time and cost burden increases significantly for patients
Solution Approach 1:
The patent applies preliminary action by measuring neural complexity through EEG before initiating antidepressant treatment. This baseline assessment predicts which patients are likely to respond to specific antidepressant classes, allowing clinicians to select the most probable effective medication from the outset rather than sequentially trying multiple agents, thereby preventing time loss before effective treatment is found
3Measurement precision
If EEG measures of neural complexity are used to predict antidepressant response, then medication selection precision improves, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts the critical predictive information from complex EEG data by focusing on a specific derived metric: neural complexity. Rather than requiring clinicians to interpret entire EEG spectra or multiple complex parameters, the system extracts the essential predictive signal (neural complexity measures) that correlates with antidepressant response, simplifying the clinical application while maintaining high predictive precision
Data Source
AI summary
This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.